Dabrafenib was also a selective inhibitor of BRAF kinase for patients suffering from BRAF-mutated melanoma, advanced non-small cell lung cancer, and anaplastic thyroid cancer harboring the BRAFV600E mutation (Puszkiel et al., 2019). This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.